Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Roivant Sciences

< Previous 1 2 Next >
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Tickers OGN ROIV
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Tickers OGN ROIV
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Tickers IMVT ROIV
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Tickers ROIV ROIVW
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.